FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q3 2024

SEC EDGAR SourceSEC Filings

Top Holdings165 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

5.3M$3B13.4%
Decreased

HESS CORP

6.4M$875.2M3.8%
4 qtrssince 2023-Q4
Decreased
0
RSPRSP
PUT

INVESCO S&P 500 EQUAL WEIGHT

4.4M$788.3M3.5%
New

IQVIA HOLDINGS INC

3.2M$751.5M3.3%$170.94+37.35%
24 qtrssince 2018-Q4
Increased
63

EXELIXIS INC

25.4M$659.4M2.9%$19.15+35.56%
24 qtrssince 2018-Q4
Decreased
0

UNITEDHEALTH GROUP INC

1.1M$641.9M2.8%$458.87+23.28%
7 qtrssince 2023-Q1
Decreased
0

MICROSOFT CORP

1.5M$631.1M2.8%$252.29+68.08%
24 qtrssince 2018-Q4
Increased
65

AON PLC

1.7M$590.3M2.6%$303.01+12.99%
3 qtrssince 2024-Q1
Decreased
0

NATERA INC

4.6M$578.6M2.5%$66.85+88.05%
14 qtrssince 2021-Q2
Increased
55

TRANSUNION

5.5M$573.3M2.5%$86.03+20.02%
24 qtrssince 2018-Q4
Decreased
0

WALT DISNEY CO/THE

5.8M$560.7M2.5%$96.25-1.77%
2 qtrssince 2024-Q2
Increased
78

SALESFORCE.COM INC

2M$559.7M2.5%$201.91+35.97%
20 qtrssince 2019-Q4
Decreased
0

REVOLUTION MEDICINES INC

11.3M$513.3M2.3%$33.17+33.17%
15 qtrssince 2021-Q1
Increased
62
CTLTCTLTDelisted

CATALENT INC

8.4M$508.4M2.2%
4 qtrssince 2023-Q4
Increased
59

NEW YORK TIMES CO-A

8.7M$486.8M2.1%$41.34+31.49%
18 qtrssince 2020-Q2
Decreased
0

BOSTON SCIENTIFIC CORP

5.4M$454.7M2.0%$51.33+62.38%
17 qtrssince 2020-Q3
Increased
63

ARAMARK

11.6M$450.7M2.0%$25.80+47.25%
16 qtrssince 2020-Q4
Decreased
0

THERMO FISHER SCIENTIFIC INC

709,456$438.8M1.9%$432.36+41.50%
20 qtrssince 2019-Q4
Decreased
0

ALPHABET INC-CL C

2.4M$403M1.8%$117.62+39.82%
24 qtrssince 2018-Q4
Increased
63

WABTEC CORP

2.2M$402M1.8%$83.08+118.08%
24 qtrssince 2018-Q4
Increased
49
$22.8B
AUM
165
Positions
Q3 2024
Filing
Rating · 1.5
Quarterly Portfolio Change
+9%Q2'23$19.9B+8%Q3'23$21.4B+2%Q4'23$21.9B+8%Q1'24$23.6B-1%Q2'24$23.3B-2%Q3'24$22.8B
Activity profile
$ moved · Q3'24
New19%Increased26%Decreased50%Exited6%
Composition
Equity vs derivatives
Equity80%Puts20%Calls0%
Holding period
Avg 2.2 years
<1Q10%1-4Q28%1-2Y15%2Y+47%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $22.8B across 165 positions as of Q3 2024. Top holdings: SPY (13.4%), HES (3.8%), RSP (3.5%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q3 2024 Summary

Active quarter - 21 new positions, 23 exits, 42 increased. Top move: DIS (INCREASED, conviction 78). Portfolio: $22.8B across 165 positions.

Top holdings by portfolio weight

Total AUM$18B
HES3.84%
IQV3.30%
EXEL2.89%
UNH2.82%
MSFT2.77%
AON2.59%
NTRA2.54%
TRU2.51%
DIS2.46%
CRM2.46%
Other2.25%

Portfolio allocation by GICS sector

Sectors11
Healthcare35.81%
Unknown16.86%
Technology13.51%
Financial Services11.87%
Communication Services8.32%
Industrials6.71%
Real Estate2.84%
Consumer Cyclical1.74%
Basic Materials1.18%
Consumer Defensive1.16%
Other0.01%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track Record60
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used